1-20 of 213
Noopur Raje
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Clinical Trials & Observations
Sikander Ailawadhi, Bertrand Arnulf, Krina Patel, Michele Cavo, Ajay K. Nooka, Salomon Manier, Natalie Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott Solomon, Ingerid Weum Abrahamsen, Rachid Baz, Annemiek Broijl, Christine Chen, Sundar Jagannath, Noopur Raje, Christof Scheid, Michel Delforge, Reuben Benjamin, Thomas Pabst, Shinsuke Iida, Jesús Berdeja, Sergio Giralt, Anna Truppel-Hartmann, Yanping Chen, Xiaobo Zhong, Fan Wu, Julia Piasecki, Laurie Eliason, Devender Dhanda, Jasper Felten, Andrea Caia, Mark Cook, Mihaela Popa McKiver, Paula Rodríguez-Otero
Journal: Blood
Blood (2024) 144 (23): 2389–2401.
https://doi.org/10.1182/blood.2024024582
Published: 2024
Includes: Supplemental data
Journal Articles

Design and Methodological Considerations for Real World Data-Derived Progression-Free Survival in Multiple Myeloma

Jocelyn R Wang, Jennifer Hayden, Yiyang Yue, Craig S Meyer, Ryan W Gan, Youyi Zhang, Benjamin Ackerman, Pranay Mohanty, James Roose, Jennifer L Lund, Sebastian Schneeweiss, Janick Weberpals, Omar Nadeem, Sikander Ailawadhi, Noopur Raje, Smith Giri, Juned Siddique, Laura Hester, Kelly Reid, Robin Carson, Khaled Sarsour, Ashita Batavia
Journal: Blood
Blood (2024) 144 (Supplement 1): 3763.
https://doi.org/10.1182/blood-2024-199224
Published: 2024
Journal Articles

Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial

Irwindeep Sandhu, Paul G. Richardson, Albert Oriol, Darrell White, Richard Leblanc, Noopur Raje, Enrique M. Ocio, Aurore Perrot, Thierry Facon, Cesar Rodriguez, Ralph Wäsch, Meletios A. Dimopoulos, Tracy T. Chow, Allison Gaudy, Jing Gong, Zehua Zhou, Tiziana Civardi, Joseph T. Hadala, Yue Zhu, Jessica Katz, Marc S. Raab
Journal: Blood
Blood (2024) 144 (Supplement 1): 1025.
https://doi.org/10.1182/blood-2024-198408
Published: 2024
Journal Articles

First-in-Human Phase 1 Study of SAR442257 in Patients with Relapsed/Refractory Multiple Myeloma and Non-Hodgkin Lymphoma

Fredrik Schjesvold, Tomas Jelinek, Kamila Polgarova, Ludek Pour, Sung-Soo Yoon, Won Seog Kim, Alexander Fosså, Jesús F. San-Miguel, Miguel Canales, Paula Rodríguez-Otero, Albert Oriol, Javier de la Rubia, Joaquín Martínez-Lopez, Sonia González De Villambrosia, Prashant Kapoor, Ola Landgren, James Edward Hoffman, Noopur Raje, Hongfang Wang, Kunal Jhunjhunwala, Liang Zhao, Zhini Wang, Mony Morisse, Helgi Van de Velde, Nitya Nathwani
Journal: Blood
Blood (2024) 144 (Supplement 1): 1992.
https://doi.org/10.1182/blood-2024-204614
Published: 2024
Journal Articles

Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma

Joshua Gustine, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Marcela Maus, Matthew J. Frigault, Noopur Raje
Journal: Blood
Blood (2024) 144 (Supplement 1): 79.
https://doi.org/10.1182/blood-2024-212135
Published: 2024
Journal Articles

Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 34-Month Median Follow-up

Michael R Bishop, Jacalyn Rosenblatt, Binod Dhakal, Noopur Raje, Daniella Cook, Mahmoud R. Gaballa, Estelle Emmanuel-Alejandro, Danielle Nissen, Kamalika Banerjee, Rebecca J Chan, Ana Kostic, Christopher R. Heery, Tim Welliver, David Avigan, Andrzej J Jakubowiak, Matthew Frigault
Journal: Blood
Blood (2024) 144 (Supplement 1): 4825.
https://doi.org/10.1182/blood-2024-201080
Published: 2024
Journal Articles

Clonal Hematopoiesis of Indeterminate Potential Does Not Impact Overall Survival in Multiple Myeloma

Farah Rexha, Joshua Gustine, Ryan Han, Rie Nakamoto-Matsubara, Cristina Panaroni, Rajib Shome, Valentina Nardi, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, Noopur Raje
Journal: Blood
Blood (2024) 144 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2024-211622
Published: 2024
Journal Articles

Outcomes of Patients By High-Risk Cytogenetic Abnormalities in a Phase II Study of Isatuximab, Weekly Carfilzomib, Lenalidomide, Dexamethasone in Newly Diagnosed, Multiple Myeloma (The SKylaRk Trial) Who Deferred Transplant

Elizabeth K. O'Donnell, Clifton C. Mo, Omar Nadeem, Jacob Laubach, Jacalyn Rosenblatt, Nikhil C. Munshi, Shonali Midha, Diana Cirstea, Paul G. Richardson, Noopur Raje, Andrew J. Yee
Journal: Blood
Blood (2024) 144 (Supplement 1): 4747.
https://doi.org/10.1182/blood-2024-201768
Published: 2024
Journal Articles

Biological Correlatives of Efficacy and Toxicity of BCMA Targeting CAR T Cell Therapy in a Real-World Setting

Charlotte Graham, Aiyana Parker, Xiaomeng Sun, Nicholas J. Haradhvala, Maria Dolaher, Kevin Lindell, Deshea Harris, Won-Ho Lee, Kiana J Graham, Hannah K Nolan, Viktoria Blumenberg, David J Bozym, Alex Li, Hana Cho, Estelle Emmanuel-Alejandro, Arienne R Annati, Julianne Marie Gildea, Alexis Barselau, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Noopur Raje, Gad Getz, Mark B Leick, Matthew Frigault, Kathleen Gallagher, Marcela V Maus
Journal: Blood
Blood (2024) 144 (Supplement 1): 7126.
https://doi.org/10.1182/blood-2024-194895
Published: 2024
Journal Articles

Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Bruno Paiva, Irene Manrique, Ethan G. Thompson, Timothy B. Campbell, Camila Guerrero, Nathan Martin, Larry D Anderson, Jr., Jesus G Berdeja, Sagar Lonial, Noopur Raje, Yi Lin, Philippe Moreau, Jesús F. San-Miguel, Nikhil C. Munshi, Shari Kaiser
Journal: Blood
Blood (2024) 144 (Supplement 1): 900.
https://doi.org/10.1182/blood-2024-203007
Published: 2024
Journal Articles

A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C. Mo, Andrew J. Yee, Omar Nadeem, Andrew R. Branagan, Jacob Laubach, Jacalyn Rosenblatt, Nora Horick, Paul G. Richardson, Noopur Raje, Diana Cirstea
Journal: Blood
Blood (2023) 142 (Supplement 1): 4671.
https://doi.org/10.1182/blood-2023-181019
Published: 2023
Journal Articles

Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series

Narsis Attar, Diana Cirstea, Andrew R. Branagan, Andrew J. Yee, Matthew J. Frigault, Noopur Raje
Journal: Blood
Blood (2023) 142 (Supplement 1): 6924.
https://doi.org/10.1182/blood-2023-182212
Published: 2023
Journal Articles

Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells

Clinical Trials & Observations
Philipp Karschnia, Kevin C. Miller, Andrew J. Yee, Kai Rejeski, P. Connor Johnson, Noopur Raje, Matthew J. Frigault, Jorg Dietrich
Journal: Blood
Blood (2023) 142 (14): 1243–1248.
https://doi.org/10.1182/blood.2023020571
Published: 2023
Journal Articles

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort a of the Magnetismm-3 Study

Nizar Jacques Bahlis, Michael H. Tomasson, Mohamad Mohty, Ruben Niesvizky, Ajay K. Nooka, Salomon Manier, Christopher Maisel, Yogesh Jethava, Joaquin Martinez-Lopez, H Miles Prince, Bertrand Arnulf, Paula Rodriguez Otero, Guenther Koehne, Cyrille Touzeau, Noopur Raje, Shinsuke Iida, Marc-Steffen Raab, Eric Leip, Sharon Sullivan, Umberto Conte, Andrea Viqueira, Alexander M Lesokhin
Journal: Blood
Blood (2022) 140 (Supplement 1): 391–393.
https://doi.org/10.1182/blood-2022-162440
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 Maia Study

Shaji K Kumar, Philippe Moreau, Nizar Jacques Bahlis, Thierry Facon, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Saad Usmani
Journal: Blood
Blood (2022) 140 (Supplement 1): 10150–10153.
https://doi.org/10.1182/blood-2022-163335
Published: 2022
Journal Articles

Magnetismm-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Ola Landgren, Dickran Kazandjian, Ashleigh O'Connell, Gregory Finn, Noopur Raje
Journal: Blood
Blood (2022) 140 (Supplement 1): 10172–10173.
https://doi.org/10.1182/blood-2022-166854
Published: 2022
Journal Articles

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

Elizabeth K. O'Donnell, Clifton C Mo, Omar Nadeem, Andrew J. Yee, Andrew R. Branagan, Jacob Laubach, Marilyn T. Gammon, Kathleen J. Lively, Lisette Packer, Cynthia C. Harrington, Emerentia Agyemang, Jacalyn Rosenblatt, Nora K. Horick, Paul G. Richardson, Noopur Raje
Journal: Blood
Blood (2022) 140 (Supplement 1): 7282–7283.
https://doi.org/10.1182/blood-2022-156328
Published: 2022
Journal Articles

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Hani Hassoun, Susanna J. Jacobus, Paul G. Richardson, Jeffrey A. Zonder, Peter M. Voorhees, Jonathan L. Kaufman, Andrew J. Yee, Emma C. Scott, Pallawi Torka, Edward Libby, Brandi Reeves, Michael L. Wang, Larry D. Anderson, Jr., Carter Milner, Cristina J. Gasparetto, Mounzer Agha, Abdullah Khan, David Duane Hurd, David Avigan, Caitlin Costello, Andrzej Jakubowiak, Sagar Lonial, Noopur Raje, Eva Medvedova, Philip L. McCarthy, Robert Z. Orlowski, Omar Nadeem, Jacob P. Laubach, Marcelo C. Pasquini, Sergio A. Giralt, Kelly Masone, Mehmet K. Samur, Aurore Perrot, Philippe Moreau, Herve Avet-Loiseau, Edie A. Weller, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood
Blood (2022) 140 (Supplement 1): 4834–4838.
https://doi.org/10.1182/blood-2022-162741
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy

Johannes M. Waldschmidt, Sankalp Arora, Tushara Vijaykumar, Noori Sotudeh, Praveen Anand, Hannah Stuart, Julia Frede, Tim Campbell, Shari M. Kaiser, Manisha Lamba, Nikhil C Munshi, Kenneth C. Anderson, Andrew J. Yee, Birgit Knoechel, Jens G. Lohr, Noopur Raje
Journal: Blood
Blood (2022) 140 (Supplement 1): 9925–9926.
https://doi.org/10.1182/blood-2022-168734
Published: 2022